Israel's Therapix gets positive Tourette's drug trial results

JERUSALEM (Reuters) – Israel’s Therapix Biosciences announced positive results on Monday from a Phase IIa trial of its cannabinoid-based drug to treat Tourette syndrome (TS), sending its stock price jumping.

Source: Reuters Medical News

Leave a Reply

Your email address will not be published. Required fields are marked *